10 Apr Pharmazac launched the new product Vasitimb® / ezetimibe + simvastatin
Pharmazac launched the new product Vasitimb / ezetimibe + simvastatin for theprevention of cardiovascular events, for hypercholesterlaemia and for theHomozygous Familial Hypercholesterolaemia.
Prevention of Cardiovascular Events
Vasitimb is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not.
Vasitimb is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:
• patients not appropriately controlled with a statin alone
• patients already treated with a statin and ezetimibe
Homozygous Familial Hypercholesterolaemia (HoFH)
Vasitimb is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g., low-density lipoprotein [LDL] apheresis).